This quarter's results are backward-looking and immaterial for a pre-revenue biotech awaiting two PDUFA catalysts. The stock will trade on the binary outcomes of FDA approvals for bezuclastinib in GIST (Nov 30) and NonAdvSM (Dec 30) — not on a $0.04 EPS miss on an expected negative number. Monitor street-side analyst updates on launch revenue estimates and any FDA advisory committee briefing documents ahead of the PDUFA dates.
Price Chart
Executive Summary
Cogent Biosciences reported Q2 2026 net loss of $96.4 million (EPS $-0.60 vs consensus $-0.56, a 6.2% miss) as R&D and G&A expenses scaled for commercial readiness ahead of dual PDUFA dates for bezuclastinib in GIST (Nov 30) and NonAdvSM (Dec 30). Cash position of $792.3 million plus $73.6 million in post-quarter ATM proceeds provides runway into late 2028, but the quarter's results are secondary to the binary regulatory catalysts.
Key Financial Metrics
Key Facts
- Net loss widened to $96.4M in Q2 2026 from $73.5M in Q2 2025, driven by increased R&D ($70.8M vs $62.2M) and G&A ($31.8M vs $13.4M) as the company builds commercial infrastructure
- Cash, equivalents and marketable securities stood at $792.3M as of June 30, 2026; pro forma cash of $865.9M including $73.6M in ATM proceeds
- EPS of $-0.60 missed consensus estimate of $-0.56 by 6.2%, a modest miss for a pre-revenue biotech where EPS is driven by expense timing, not business deterioration
- NDA for bezuclastinib in GIST accepted with priority review, PDUFA date of November 30, 2026
- NDA for bezuclastinib in NonAdvSM submitted, PDUFA date of December 30, 2026; NDA for AdvSM submitted June 30, 2026
- Inducement grants of 226,700 options and 189,700 RSUs made to 59 new commercial employees on August 4 and August 10, 2026
Financial Impact
Net loss $96.4M; operating expenses $102.6M; no revenue; cash burn rate approximately $100M/quarter
Risk Factors
- FDA could issue Complete Response Letter for bezuclastinib in GIST or NonAdvSM, delaying or denying approval
- Commercial execution risk: if approved, investor expectations around launch trajectory may be high given the $7.2B market cap
- Cash burn may accelerate with commercial buildout; post-quarter ATM filing suggests potential need for additional capital beyond late 2028
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341783 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Aug 10, 2026 7w ago | Press Release | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Aug 9, 2026 7w ago | Institutional Cluster | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.02 (−6.28%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.02 (−6.28%) |
May 30, 2026 17w ago | Press Release | $34.81 $38.70 | ▲ +11.18% | ▲ +12.47% | $31.02 (−10.89%) |
May 28, 2026 18w ago | Press Release | $35.38 $38.10 | ▲ +7.69% | ▲ +10.83% | $31.02 (−12.32%) |
May 5, 2026 21w ago | 8-K | $36.98 $32.76 | ▼ −11.41% | ▼ −16.37% | $31.02 (−16.12%) |
Apr 17, 2026 24w ago | Press Release | $37.25 $34.19 | ▼ −8.21% | ▼ −13.59% | $31.02 (−16.72%) |
Apr 1, 2026 26w ago | Press Release | $35.24 $35.87 | ▲ +1.79% | ▼ −7.93% | $31.02 (−11.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access